Ocugen slides 13% on gene therapy data that trails interim results
Phase 2 OCU410 trial for dry AMD shows 31% lesion reduction, below earlier 54% interim readout
Ocugen shares plunged 13.4% to $1.82 on Tuesday after the biotechnology company released final Phase 2 data for its experimental gene therapy that failed to match earlier interim results, dampening investor enthusiasm for a treatment aimed at one of ophthalmology's most challenging conditions.
The clinical-stage biotech, which focuses on therapies for diseases of blindness, announced that its OCU410 gene therapy achieved a 31% reduction in lesion growth compared to control groups at 12 months, with statistical significance (p<0.05). While the company framed the results as positive and highlighted a potential twofold treatment benefit over currently approved therapies, the figure fell short of the 46% to 54% reduction reported in January when preliminary data from the same trial was released.
The $669 million market-cap company, which trades on the Nasdaq under ticker OCGN, has seen its stock decline below both its 50-day moving average of $1.72 and 200-day average of $1.37, reflecting ongoing uncertainty about the commercial potential of its gene therapy pipeline for age-related macular degeneration. Despite the sell-off, Ocugen's shares remain up more than 200% over the past year, having rallied from a 52-week low of $0.57 to a recent high of $2.73.
"We have confirmed robust treatment effect from a well-controlled Phase 2 trial of a genetic medicine for GA," said Dr. Shankar Musunuri, Ocugen's chairman and chief executive officer, in a statement. "Now we can move on to Phase 3 with a high degree of confidence."
The company plans to initiate a Phase 3 registrational trial in the third quarter of 2026, with a target for submitting a Biologics License Application to regulators in 2028. The Phase 2 ArMaDa trial randomized 51 patients aged 50 and older to receive either a medium dose, a high dose, or no treatment in a control group. No serious adverse events related to OCU410 were reported across all dose cohorts.
Ocugen faces a crowded and competitive market for geographic atrophy, a progressive form of dry age-related macular degeneration that leads to irreversible vision loss. Two treatments are already approved in the United States: Apellis Pharmaceuticals' SYFOVRE, which generated $587 million in U.S. net product revenue in 2025, and Astellas Pharma's Izervay, which reported $110 million in U.S. sales for its first fiscal quarter of 2025.
Unlike those approved therapies, which require regular injections and target specific pathways in the complement system, OCU410 is designed as a one-time gene therapy that addresses multiple pathways involved in retinal health, including oxidative stress response, complement regulation, inflammation, and lipid metabolism. This multi-target approach aims to eliminate the chronic treatment burden that patients with geographic atrophy currently face.
Analysts maintain a bullish outlook on Ocugen despite Tuesday's sell-off, with an average price target of $10.60, according to market data. Five analysts rate the stock a buy or strong buy, while none recommend holding or selling. The consensus target suggests nearly 500% upside from current levels, reflecting the significant commercial opportunity if OCU410 successfully advances through late-stage trials and gains regulatory approval.
"We are incorporating these learnings into an anticipated Phase 3 pivotal confirmatory trial with up to 300 subjects and an adaptive design," said Huma Qamar, Ocugen's chief medical officer. The adaptive design allows researchers to modify the trial based on interim results, potentially increasing efficiency in drug development.
Beyond OCU410, Ocugen's pipeline includes a COVID-19 vaccine candidate that has not advanced as rapidly as initially anticipated during the pandemic, leaving the geographic atrophy program as the company's primary value driver. The company reported negative earnings per share of $0.23 for the trailing twelve months, with revenue of just $4.4 million, reflecting its pre-commercial stage.
The discrepancy between Ocugen's interim and final Phase 2 results highlights the risks inherent in biopharmaceutical development, where small sample sizes in early data readouts can sometimes overstate treatment effects. The January interim data had shown the medium dose achieving a 54% lesion reduction with statistical significance based on a sample of just 10 patients, while the final data incorporated the full trial population.
Investors will be watching closely for additional details when Ocugen presents the complete Phase 2 dataset at an upcoming medical conference, which could provide more clarity on the strength and consistency of the treatment effect across different patient subgroups and endpoints.